|
業務類別
|
-- |
|
業務概覽
|
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe. |
| 公司地址
| 655 Elizabeth Street, Melbourne, VIC, AUS, 3000 |
| 電話號碼
| +61 393891911 |
| 傳真號碼
| +61 393891434 |
| 公司網頁
| https://www.csl.com |
| 員工數量
| 29000 |
| Dr. Paul McKenzie |
Director, Managing Director and Chief Executive Officer |
-- |
18/08/2025 |
|
|
| Dr. Paul McKenzie |
Director, Managing Director and Chief Executive Officer |
18/08/2025 |
| Ms. Elaine K. Sorg |
Independent Director |
18/08/2025 |
| Dr. Brian Daniels,M.D. |
Independent Director |
18/08/2025 |
| Ms. Samantha Lewis, B.A.,C.A. |
Independent Director |
18/08/2025 |
| Dr. Megan Clark |
Independent Director |
18/08/2025 |
| Ms. Marie McDonald |
Independent Director |
18/08/2025 |
| Ms. Alison Mary Watkins |
Independent Director |
18/08/2025 |
| Ms. Carolyn Hewson |
Independent Director |
18/08/2025 |
| Professor Andrew Cuthbertson, PhD |
Director |
18/08/2025 |
| Dr. Brian A. Mcnamee |
Chairman of the Board |
18/08/2025 |
|
|
|
|
